First-quarter earnings reports have trickled in for the last week and a half, but will really kick into high gear on April 26 when six biotech and pharma heavy hitters all report on the same day.
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
Mylan N.V. on April 20 released more than 400 workers from its Morgantown, West Virginia plant, most of whom were production employees.
It's been a good news-bad news 24 hours for Eli Lilly. Its closely watched RA prospect baricitinib didn't exactly sail through Monday's FDA committee meeting. But Tuesday morning, Lilly rolled out Q1 results that beat sales and earnings expectations. Upshot? Analysts are still worried about a baricitinib approval.
Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.